stockrow
Monday 2 November 2026
Export TWST’s income statement to Excel — free account
Twist Bioscience Corporation
TWST Healthcare Biotechnology
Twist Bioscience Corporation’s revenue for fiscal 2025 (year ended September 2025) was $376.6 million, up 20.3% from fiscal 2024.
- Revenue
- +23.2%
- EPS
- −264.7%
- Free cash flow
- −7.23%
- Total debt
- 0.00%
Quarter to June 2026, against a year earlier
129.86
22.92
−15.00%
Follow TWST
Alert me
| Sep '16 | Sep '17 | Sep '18 | Sep '19 | Sep '20 | Sep '21 | Sep '22 | Sep '23 | Sep '24 | Sep '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 5 | 4 | 3 | 4 | 4 | 4 | 4 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.66 | 1.66 | 1.66 | 12.06 | 33.04 | 39.00 | 9.33 | 4.45 | 8.38 | 4.47 |
Altman Z-Score |
— | — | — | 8.09 | 26.88 | 24.62 | 5.46 | 2.59 | 8.14 | 3.44 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | (1.84) | (2.16) | (0.34) | 4.45 | 5.25 | 3.82 | 1.03 | (2.56) | (2.72) |
Beneish M-Score |
— | — | — | (3.63) | (0.87) | (2.62) | (2.32) | (2.64) | (3.65) | (2.30) |
P/Operating CF |
(2.53) | (2.53) | (2.53) | (28.08) | (118.14) | (148.30) | (1,498.74) | (52.67) | (171.09) | (142.46) |
P/B ratio |
0.00 | 0.00 | 0.00 | 4.31 | 8.85 | 8.89 | 2.41 | 1.75 | 5.55 | 3.56 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 4.36 | 8.89 | 9.56 | 2.95 | 2.26 | 7.04 | 4.46 |
EV/Sales |
(1.13) | (1.13) | (1.13) | 9.66 | 29.88 | 35.80 | 7.25 | 3.41 | 7.75 | 3.90 |
EV/EBITDA |
0.45 | 0.45 | 0.45 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
0.44 | 0.44 | 0.44 | (5.97) | (18.92) | (42.21) | (11.87) | (5.86) | (37.84) | (30.80) |
EV/FCF |
0.41 | 0.41 | 0.41 | (5.12) | (17.70) | (34.01) | (6.53) | (4.90) | (35.07) | (19.40) |
Quick Ratio |
6.53 | 6.81 | 4.65 | 4.95 | 8.78 | 8.03 | 6.01 | 5.19 | 4.38 | 3.17 |
Current Ratio |
6.80 | 7.16 | 5.16 | 5.28 | 9.29 | 8.67 | 6.58 | 5.79 | 4.88 | 3.64 |
Net Debt/EBITDA |
1.14 | 0.99 | 1.10 | 1.27 | 2.14 | 2.96 | 1.94 | 1.37 | 1.46 | 1.95 |
Debt/Assets |
0.00% | 10.69% | 8.39% | 4.14% | 1.19% | 7.79% | 8.45% | 10.20% | 0.00% | 2.34% |
Debt/Equity |
0.00 | 0.14 | 0.11 | 0.05 | 0.01 | 0.09 | 0.10 | 0.13 | 0.00 | 0.03 |
Asset Turnover |
0.05 | 0.25 | 0.25 | 0.36 | 0.31 | 0.24 | 0.24 | 0.28 | 0.45 | 0.60 |
Operating CF/Net income |
0.88 | 0.87 | 0.93 | 0.82 | 1.02 | 0.74 | 0.57 | 0.70 | 0.31 | 0.61 |
Capex/Depreciation |
(1.45) | (1.24) | (0.61) | (2.30) | (1.44) | (2.78) | (6.17) | (0.95) | (0.16) | (1.13) |
Interest Coverage |
(58.52) | (64.62) | (53.74) | (84.12) | (177.99) | (416.15) | (2,934.70) | (43,431.80) | (7,614.86) | — |
| 41.99% | 56.49% | 42.56% | 436.44% | (57.31%) | (33.17%) | (31.80%) | (28.97%) | (38.08%) | (16.43%) | |
| (102.94%) | (138.48%) | (70.72%) | (71.12%) | (47.77%) | (27.63%) | (26.19%) | (23.55%) | (30.02%) | (12.37%) | |
ROIC |
0.00% | (276.38%) | (244.70%) | (313.39%) | (171.68%) | (60.54%) | (40.13%) | (37.06%) | (70.31%) | (33.33%) |
Return on Tangible Assets |
(67.85%) | (81.00%) | (79.62%) | (71.49%) | (43.15%) | (28.83%) | (33.76%) | (42.38%) | (55.18%) | (22.59%) |
Average Days of Receivables |
116.30 | 79.53 | 77.79 | 81.23 | 106.85 | 78.74 | 72.25 | 65.62 | 40.71 | 55.27 |
Research and Development Expense of Revenue |
803.44% | 178.03% | 80.02% | 65.61% | 47.73% | 52.20% | 59.10% | 43.61% | 29.03% | 21.32% |
Selling, General and Administrative Expense of Revenue |
805.38% | 242.04% | 170.88% | 147.33% | 114.61% | 102.70% | 104.61% | 77.41% | 69.78% | 65.59% |
Intangible Assets out of Total Assets |
0.00 | 0.02 | 0.02 | 0.01 | 0.00 | 0.06 | 0.15 | 0.18 | 0.16 | 0.15 |
Share Based Compensation of Revenue |
37.77% | 17.56% | 11.65% | 20.54% | 18.97% | 27.96% | 39.13% | 12.35% | 16.27% | 17.12% |
Graham Net Nets |
1.63 | 1.63 | 1.63 | 0.19 | 0.09 | 0.08 | 0.22 | 0.25 | 0.08 | 0.10 |
Graham Number |
0.00 | 0.00 | 195.87 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(182.24%) | (182.24%) | (182.24%) | (16.71%) | (4.94%) | (2.95%) | (11.44%) | (18.78%) | (7.97%) | (4.62%) |
Free Cash Flow Yield |
(165.49%) | (165.49%) | (165.49%) | (15.66%) | (5.11%) | (2.70%) | (11.91%) | (15.61%) | (2.64%) | (4.49%) |
Revenue per Share |
1.21 | 4.45 | 9.10 | 1.98 | 2.30 | 2.74 | 3.78 | 4.31 | 5.39 | 6.30 |
Operating CF per Share |
(20.64) | (21.18) | (23.69) | (3.20) | (3.63) | (2.33) | (2.31) | (2.50) | (1.10) | (0.80) |
Capex per Share |
(3.33) | (2.61) | (1.31) | (0.54) | (0.25) | (0.56) | (1.89) | (0.49) | (0.09) | (0.47) |
Free Cash Flow per Share |
(23.97) | (23.79) | (25.00) | (3.74) | (3.88) | (2.89) | (4.20) | (2.99) | (1.19) | (1.26) |
Cash per Share |
29.90 | 25.68 | 28.91 | 5.03 | 7.40 | 9.90 | 9.37 | 5.91 | 4.76 | 3.89 |
Shareholders Equity per Share |
0.00 | 27.36 | 31.89 | 5.54 | 8.58 | 12.04 | 14.65 | 10.96 | 8.15 | 7.91 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.00 | 27.36 | 31.89 | 5.54 | 8.58 | 12.04 | 14.65 | 10.96 | 8.15 | 7.91 |
Free Cash Flow |
(44.82) | (57.63) | (69.83) | (102.67) | (152.12) | (139.30) | (226.24) | (170.25) | (69.17) | (75.63) |
Working Capital |
50.36 | 58.39 | 77.13 | 129.78 | 298.84 | 483.44 | 505.82 | 350.93 | 275.77 | 241.56 |
Capital Expenditures |
(6.23) | (6.33) | (3.67) | (14.74) | (9.87) | (27.06) | (101.86) | (27.78) | (5.08) | (28.00) |
Net Current Asset Value |
59.04 | 48.49 | 68.94 | 125.22 | 272.25 | 425.22 | 424.49 | 271.29 | 205.14 | 164.06 |
EV/EBIT |
0.41 | 0.41 | 0.41 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
2.75 | 0.59 | 0.14 | 0.27 | 0.11 | 0.20 | 0.50 | 0.11 | 0.02 | 0.07 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.29 | 0.34 | 0.49 | 0.31 | 0.27 | 0.22 | 0.12 | 0.22 | 0.31 | 0.24 |
Cash ROIC |
(66.80%) | (41.87%) | (38.90%) | (34.46%) | (24.11%) | (12.51%) | (16.45%) | (16.39%) | (9.23%) | (10.50%) |
Accounts Receivable Turnover |
1.48 | 7.02 | 6.55 | 6.21 | 4.68 | 4.82 | 5.91 | 5.81 | 7.93 | 8.19 |
Accounts Payable Turnover |
3.63 | 9.26 | 6.20 | 5.49 | 8.42 | 8.17 | 6.82 | 9.10 | 22.91 | 29.17 |
Inventory Turnover |
6.17 | 15.73 | 8.20 | 7.10 | 6.26 | 3.66 | 3.36 | 4.35 | 6.40 | 7.08 |
Average Days of Payables |
90.54 | 43.29 | 85.40 | 75.11 | 28.71 | 67.46 | 61.46 | 33.01 | 3.31 | 21.82 |
Days of Inventory on Hand |
47.58 | 27.76 | 68.35 | 56.41 | 73.05 | 143.97 | 120.23 | 75.32 | 48.93 | 55.68 |
Average Receivables |
1.53 | 1.53 | 3.88 | 8.76 | 19.24 | 27.46 | 34.42 | 42.18 | 39.48 | 45.96 |
Average Payables |
2.59 | 2.59 | 5.19 | 8.65 | 7.30 | 9.87 | 17.50 | 17.07 | 7.84 | 6.36 |
Average Inventory |
1.53 | 1.53 | 3.93 | 6.68 | 9.81 | 22.04 | 35.55 | 35.69 | 28.07 | 26.19 |
Average Assets |
42.83 | 42.83 | 100.72 | 151.39 | 292.94 | 550.49 | 831.74 | 868.89 | 695.36 | 628.09 |
Average Common Equity |
(104.98) | (104.98) | (167.39) | (24.67) | 244.17 | 458.54 | 685.10 | 706.41 | 548.06 | 472.82 |
Columns are period end dates